These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 25862847

  • 1. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
    Aderhold C, Faber A, Grobschmidt GM, Chakraborty A, Bockmayer A, Umbreit C, Birk R, Stern-Straeter J, Hörmann K, Schultz JD.
    Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [Abstract] [Full Text] [Related]

  • 11. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, Burkholder I, Bergmann L.
    J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K, Lee JL, Park I, Park S, Ahn Y, Ahn JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C, Umbreit C, Faber A, Sauter A, Sommer JU, Birk R, Erben P, Hofheinz RD, Stern-Straeter J, Hörmann K, Schultz JD.
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [Abstract] [Full Text] [Related]

  • 14. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
    Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C.
    Anticancer Res; 2013 Nov; 33(11):4999-5004. PubMed ID: 24222142
    [Abstract] [Full Text] [Related]

  • 15. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C, Aderhold C, Faber A, Sommer JU, Sauter A, Hofheinz RD, Stern-Sträter J, Hoermann K, Schultz JD.
    Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFβ1 and TGF-β Receptor 2 in Squamous Cell Carcinoma Cells.
    Huber L, Knüttel MT, Kramer B, Zaubitzer L, Lammert A, Scherl C, Rotter N, Häussler D.
    Anticancer Res; 2024 Aug; 44(8):3287-3294. PubMed ID: 39060052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.